4-(环戊基甲酰氨)苯基硼酸 | 850568-15-9

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物 - 环羧酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(环戊基甲酰氨)苯基硼酸
• 中文别名: 4-(环戊基氨甲酰)苯硼酸；4-(环戊基氨基羰基)苯硼酸
• 英文名称: [4-(N-cyclopentylaminocarbonyl)phenyl]boronic acid
• 英文别名: {4-[(cyclopentylamino)carbonyl]phenyl}boronic acid；(4-(Cyclopentylcarbamoyl)phenyl)boronic acid；[4-(cyclopentylcarbamoyl)phenyl]boronic acid
• CAS: 850568-15-9
• 化学式: C₁₂H₁₆BNO₃
• mdl: MFCD03788418
• 分子量: 233.075
• InChiKey: VMJFATWKBZYOFO-UHFFFAOYSA-N

物化性质

• 熔点：
  196-200°C

计算性质

• 辛醇/水分配系数(LogP)：
  1.73
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  69.6
• 氢给体数：
  3
• 氢受体数：
  3

安全信息

• 危险类别码：
  R36/37/38
• 海关编码：
  2931900090
• 安全说明：
  S26,S36/37/39

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
4-(Cyclopentylaminocarbonyl)phenylboronic acid
Product Name:
Synonyms: N-Cyclopentyl 4-boronobenzamide

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
4-(Cyclopentylaminocarbonyl)phenylboronic acid
Ingredient name:
CAS number: 850568-15-9

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C12H16BNO3
Molecular weight: 233.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(环戊基甲酰氨)苯基硼酸 、 2-(2-氯吡啶-4-基)-1,5,6,7-四氢-4H-吡咯并[3,2-c]吡啶-4-酮 在 四(三苯基膦)钯 caesium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 Pyrrolopyridine, 33
  参考文献：
  名称：

  Pyrrolopyridine Inhibitors of Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MK-2)

  摘要：

  A new class of potent kinase inhibitors selective for mitogen-activated protein kinase-activated protein kinase 2 (MAPKAP-K2 or MK-2) for the treatment of rheumatoid arthritis has been prepared and evaluated. These inhibitors have IC50 values as low as 10 nM against the target and have good selectivity profiles against a number of kinases including CDK2, ERK, JNK, and p38. These MK-2 inhibitors have been shown to suppress TNF alpha production in U397 cells and to be efficacious in an acute inflammation model. The structure-activity relationships of this series, the selectivity for MK-2 and their activity in both in vitro and in vivo models are discussed. The observed selectivity is discussed with the aid of an MK-2/inhibitor crystal structure.

  DOI：

  10.1021/jm0611004

文献信息

• Nickel-Catalyzed Cross Couplings of Benzylic Ammonium Salts and Boronic Acids: Stereospecific Formation of Diarylethanes via C–N Bond Activation
  作者：Prantik Maity、Danielle M. Shacklady-McAtee、Glenn P. A. Yap、Eric R. Sirianni、Mary P. Watson

  DOI：10.1021/ja3089422

  日期：2013.1.9

  We have developed a nickel-catalyzed cross coupling of benzylic ammonium triflates with aryl boronic acids to afford diarylmethanes and diarylethanes. This reaction proceeds under mild reaction conditions and with exceptional functional group tolerance. Further, it transforms branched benzylic ammonium salts to diarylethanes with excellent chirality transfer, offering a new strategy for the synthesis

  我们开发了一种镍催化的苄基三氟甲磺酸铵与芳基硼酸的交叉偶联，以提供二芳基甲烷和二芳基乙烷。该反应在温和的反应条件下进行，具有出色的官能团耐受性。此外，它以优异的手性转移将支化的苄基铵盐转化为二芳基乙烷，为从容易获得的手性苄基胺合成高度对映体富集的二芳基乙烷提供了一种新策略。
• Nanoscale synthesis and affinity ranking
  作者：Nathan J. Gesmundo、Bérengère Sauvagnat、Patrick J. Curran、Matthew P. Richards、Christine L. Andrews、Peter J. Dandliker、Tim Cernak

  DOI：10.1038/s41586-018-0056-8

  日期：2018.5

  Most drugs are developed through iterative rounds of chemical synthesis and biochemical testing to optimize the affinity of a particular compound for a protein target of therapeutic interest. This process is challenging because candidate molecules must be selected from a chemical space of more than 1060 drug-like possibilities 1 , and a single reaction used to synthesize each molecule has more than 107 plausible permutations of catalysts, ligands, additives and other parameters 2 . The merger of a method for high-throughput chemical synthesis with a biochemical assay would facilitate the exploration of this enormous search space and streamline the hunt for new drugs and chemical probes. Miniaturized high-throughput chemical synthesis3–7 has enabled rapid evaluation of reaction space, but so far the merger of such syntheses with bioassays has been achieved with only low-density reaction arrays, which analyse only a handful of analogues prepared under a single reaction condition8–13. High-density chemical synthesis approaches that have been coupled to bioassays, including on-bead 14 , on-surface 15 , on-DNA 16 and mass-encoding technologies 17 , greatly reduce material requirements, but they require the covalent linkage of substrates to a potentially reactive support, must be performed under high dilution and must operate in a mixture format. These reaction attributes limit the application of transition-metal catalysts, which are easily poisoned by the many functional groups present in a complex mixture, and of transformations for which the kinetics require a high concentration of reactant. Here we couple high-throughput nanomole-scale synthesis with a label-free affinity-selection mass spectrometry bioassay. Each reaction is performed at a 0.1-molar concentration in a discrete well to enable transition-metal catalysis while consuming less than 0.05 milligrams of substrate per reaction. The affinity-selection mass spectrometry bioassay is then used to rank the affinity of the reaction products to target proteins, removing the need for time-intensive reaction purification. This method enables the primary synthesis and testing steps that are critical to the invention of protein inhibitors to be performed rapidly and with minimal consumption of starting materials. A system that combines nanoscale synthesis and affinity ranking enables high-throughput screening of reaction conditions and bioactivity for a given protein target, accelerating the process of drug discovery.

  大多数药物都是通过反复的化学合成和生化测试来开发，以优化特定化合物与治疗感兴趣的蛋白质靶点的亲和力。这一过程颇具挑战性，因为候选分子必须从超过10^60种类药物可能性的化学空间中选出，而用于合成每个分子的单一反应中催化剂、配体、添加剂和其他参数的合理排列组合超过10^7种。将高通量化学合成方法与生化分析方法相结合，将有助于探索这一巨大的搜索空间，并简化新型药物和化学探针的寻找过程。微型化高通量化学合成技术已经能够快速评估反应空间，但迄今为止，这种合成方法与生物分析方法的结合，仅限于低密度反应阵列，即在单一反应条件下仅分析少量类似物。高密度化学合成方法与生物分析方法相结合，包括使用珠子上、表面上、DNA上和质量编码等技术，大大减少了材料需求，但这些方法要求底物与潜在的反应性载体共价连接，必须在高度稀释的情况下进行，并且必须在混合物的形式下运作。这些反应特性限制了过渡金属催化剂的应用，因为过渡金属催化剂很容易受到复杂混合物中存在的多种官能团的毒害，而且对于动力学需要高浓度反应物的反应过程也不适用。本研究将高通量纳摩尔级合成与无标记的亲和选择质谱生物分析相结合，使得每个反应在0.1摩尔浓度的条件下进行，既可能实现过渡金属催化，又使得每个反应消耗的底物不足0.05毫克。然后，使用亲和选择质谱生物分析法对反应产物与靶蛋白的亲和力进行排序，省去了耗时的反应纯化步骤。该方法使得对蛋白质抑制剂发明至关重要的初级合成和测试步骤能够快速完成，且起始材料消耗最小。纳米级合成和亲和力排序相结合的系统可以实现对给定蛋白质靶点的反应条件和生物活性进行高通量筛选，从而加速药物发现过程。
• [EN] SELECTIVE ESTROGEN RECEPTOR MODULATORS<br/>[FR] MODULATEURS SELECTIFS DU RECEPTEUR DES OESTROGENES
  申请人：LILLY CO ELI

  公开号：WO2005073205A1

  公开（公告）日：2005-08-11

  The present invention relates to a selective estrogen receptor modulators of formula I (I); or a pharmaceutical acid addition salt thereof; and of formula II (II); or a pharmaceutical salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.

  本发明涉及一种化学式I（I）的选择性雌激素受体调节剂；或其药用酸盐；以及化学式II（II）的化合物；或其药用盐；可用于治疗子宫内膜异位症和/或子宫平滑肌瘤。
• Selective estrogen receptor modulators
  申请人：Dally Dean Robert

  公开号：US20070111988A1

  公开（公告）日：2007-05-17

  The present invention relates to a selective estrogen receptor modulators of formula I (I); or a pharmaceutical acid addition salt thereof; and of formula II (II); or a pharmaceutical salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.

  本发明涉及公式I（I）的选择性雌激素受体调节剂; 或其药物酸加盐; 以及公式II（II）的药物盐; 例如，用于治疗子宫内膜异位症和/或子宫平滑肌瘤/平滑肌瘤。
• BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS
  申请人：Fang Jing

  公开号：US20100029650A1

  公开（公告）日：2010-02-04

  The present invention relates to novel compounds that are useful in the treatment of metabolic disorders, particularly type II diabetes mellitus and related disorders, and also to the methods for the making and use of such compounds.

  本发明涉及一种新型化合物，其在代谢性疾病的治疗中具有用途，特别是在II型糖尿病及相关疾病的治疗中，并且还涉及制备和使用这种化合物的方法。